기사본문
ABL Bio Enters into L/O agreement with TRIGR Therapeutics for ABL001
입력 2018-11-30 23:45 수정 2018-11-30 23:45
바이오스펙테이터 Sungmin Kim 기자
ABL Bio announced on November 30th that it had signed an out-licensing agreement with TRIGR Therapeutics for the ABL001, a bispecific antibody candidate targeting two important angiogenic factors VEGF and DLL4.
Under the agreement, TRIGR is responsible for all subsequent global clinical development and commercialization activities for ABL001 in oncology (excluding the Republic of Korea) and ophthalmology (excluding the Republic of Korea and Japan). ABL Bio will receive an upfront payment of $5 million and is eligible to receive up to $595 million in total with an upfront, clinical and commercial milestone payments and royalties on sales of ABL001.
ABL001 is currently in a dose escalation Phase 1a study being conducted at the Samsung Medical Center in South Korea. ABL Bio and TRIGR Therapeutics are planning to continue phase 1b study in the form of joint development.
To date, 12 patients have been dosed with ABL001 and no dose-limiting toxicities (DLTs) have been reported. Based on preliminary patient data, ABL001 single agent clinical activity has been demonstrated across all dose levels among heavily pre-treated (5+ lines of prior therapy) cancer patients with solid tumors including gastric, colon, GIST, and ovarian cancers. At the mid-dose cohort level, half of the patients have experienced durable clinical benefit in terms of tumor stabilization (stable disease).
“The latest development with TRIGR is the 5th agreement of the ABL Bio’s out-licensing deals soby far and the 4th of the year in 2018 that ABL Bio has reached. This agreement continues to exemplify that our company’s outstanding bispecific antibody research and development capabilities have been globally recognized by the broader pharmaceutical companies and academic institutions.” said Dr. Sang Hoon Lee, CEO of ABL Bio. “With globally recognized technical capabilities, we are striving for leading the innovative bispecific antibody immunotherapies.”
ABL Bio filed a registration statement on November 14th and is aiming to be listed on KOSDAQ (The Korea Securities Dealers Association Automated Quotation) in mid-December.
